In Canada, the analytical landscape is undergoing a fundamental overhaul. The Prohibition of Certain Toxic Substances Regulations, 2025 (published December 31, 2025), will officially repeal and replace the 2012 framework on June 30, 2026.
To meet these new requirements, laboratories must address the following critical updates:
- Expanded PFAS scope: The 2025 regulations move beyond legacy PFOS and PFOA to restrict the broader class of long-chain perfluorinated carboxylic acids (LC-PFCAs), including their salts and precursors.
- Class-based enforcement: Following the 2025 State of PFAS Report, Environment and Climate Change Canada (ECCC) has signaled a preference for managing PFAS as a broad class. For laboratories, this necessitates a move toward total organic fluorine (TOF) and adsorbable organic fluorine (AOF) screening via combustion ion chromatography (CIC).
- Flame retardant mandates: The update introduces strict new bans on dechlorane plus (DP) and decabromodiphenyl ethane (DBDPE). Since these are prevalent in electronics and automotive polymers, labs must validate high-throughput GC-MS methodologies for complex matrices.
These Canadian mandates represent a significant departure from individual analyte monitoring, necessitating a "total fluorine" mindset for full compliance.
U.S. FDA Human Foods Program (HFP) 2026: What Chemists Need to Know
While the U.S. Environmental Protection Agency (EPA) oversees environmental PFAS testing regulations, the Food & Drug Administration (FDA)'s restructured Human Foods Program prioritizes chemical safety in the food supply.
The End of "Self-GRAS" (Generally Recognized as Safe)
The most disruptive change in 2026 is the FDA GRAS Reform. A proposed regulation will require mandatory safety notices for all new substances. This effectively eliminates "self-affirmed GRAS" status, forcing industry players to provide rigorous analytical data—likely requiring LC-HRMS for characterization—to a public inventory.
2026 Post-Market Safety Priorities
The FDA is initiating rigorous safety reviews of legacy food chemicals, using its new Systematic Post-Market Assessment process to prioritize routine screening in the following areas:
Endocrine disruptors: Phthalates in food contact materials (FCM) are under intense scrutiny due to updated migration limits and cumulative exposure models.
Synthetic antioxidants: Butylated hydroxyanisole (BHA), Butylated hydroxytoluene (BHA), and Propylparaben are being re-evaluated for their cumulative health impacts.
PFAS in food packaging: Continued enforcement is targeting grease-proofing agents in paperboard, requiring compliance with FDA-validated LC-MS/MS methods.
By moving away from historical exemptions, the FDA is signaling a new era of transparency that requires robust analytical substantiation for every additive.
Workflow Strategy: Optimizing for 2026 Compliance
As PFAS testing regulations become more stringent, laboratory workflows must evolve from simple targeted screening to comprehensive mass balance approaches.
Regulatory Focus | Priority Analytes | Primary Analytical Methodology |
Environmental/Consumer | PFAS (class-based), DP, DBDPE | LC-MS/MS (EPA 1633), GC-MS, CIC (total fluorine) |
Food Additives | BHA, BHT, Propylparaben | Targeted GC-MS/MS |
Packaging/FCM | Phthalates, PFAS, Microplastics | Pyrolysis-GC-MS, LC-MS/MS, FTIR |
Strategic Recommendation for CTOs
To remain competitive under the 2026 mandates, laboratories should prioritize the following three operational pillars:
Transitioning to LC-MS/MS: Validating methods for the 40+ PFAS analytes typically required by EPA 1633 or equivalent Health Canada methods.
Implementing non-targeted analysis (NTA): Using high-resolution accurate mass (HRAM) tools to identify "regrettable substitutions" before they become regulatory bottlenecks.
Ultra-trace quantification: Ensuring limits of detection (LOD) meet the parts-per-quadrillion (ppq) levels increasingly demanded by global health advisories.
By standardizing these high-sensitivity protocols, labs can ensure they are prepared for both specific target lists and emerging broad-spectrum screenings.
Industry outlook: The laboratories that successfully integrate total fluorine screening with targeted GC-MS/MS and LC-MS/MS workflows will be best positioned to lead the market as these 2026 regulations take full effect.
